Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Published by: Harvard Business Publishing
Originally published in: 2002
Version: 13 May 2002

Abstract

Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme''s business model under new pressures.; Illustrates novel approach to targeting drug markets and creative ways to use external technology.

About

Abstract

Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme''s business model under new pressures.; Illustrates novel approach to targeting drug markets and creative ways to use external technology.

Related